Truist downgraded Merus (MRUS) to Hold from Buy with a price target of $97, up from $88, following the company announcing it accepted Genmab’s (GMAB) bid at “a nice premium.” The firm thinks the deal terms are “favorable, all things considered,” the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRUS: